Skip to main content
SpringerLink
Log in

Molécules inhibitrices des récepteurs du VEGF

  • Chapter
Les thérapies ciblées

Part of the book series: Oncologie pratique ((ONCOLPRAT))

  • 385 Accesses

Abstrait

Ľangiogenèse est ľun des processus clés de la croissance et la dissémination tumorale.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669–77

    Article  PubMed  CAS  Google Scholar 

  2. Soker S, Takashima S, Miao HQ, et al. (1998) Neuroplilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735–45

    Article  PubMed  CAS  Google Scholar 

  3. Paavonen K, Puolakkainen P, Jussilia L, et al. (2000) Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol 156: 1499–1504

    PubMed  CAS  Google Scholar 

  4. Mandriota SJ, Jussilia Jeltsch M, et al. (2000) Vascular endothelial growth factor C-mediated lymphangiogenesis promotes tumour metastasis. EMBO 20: 672–82

    Google Scholar 

  5. Stacker SA, Caesar C, Baldwin ME, et al. (2001) VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7: 181–91

    Article  CAS  Google Scholar 

  6. Wilhem S, Carter C, Tang L (2004) BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and tumour tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res 64: 7099–109

    Article  Google Scholar 

  7. Clark JW, Eder JP, Ryan D, et al. (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11: 5472–80

    Article  PubMed  CAS  Google Scholar 

  8. Strumberg D, Richly H, Hilger RA, et al. (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23: 965–72

    Article  PubMed  CAS  Google Scholar 

  9. Ratain MJ, Eisen T, Stadler WM, et al. (2006) Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol 24: 2505–12

    Article  PubMed  CAS  Google Scholar 

  10. Escudier B, Eisen T, Stadler WM, et al. (2007) Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N Engl J Med 356: 125–34

    Article  PubMed  CAS  Google Scholar 

  11. Eisen T, Ahmad T, Flaherty KT, et al. (2006) Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95: 581–6

    Article  PubMed  CAS  Google Scholar 

  12. Abou-Alfa GK, Scwartz L, Ricci S, et al. (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293–300

    Article  PubMed  CAS  Google Scholar 

  13. Gatzemeier U, Blumenschein G, Fosella F (2006) Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 24: 7002

    Google Scholar 

  14. Mendel DB, Laird AD, Xin X, et al. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327–37

    PubMed  CAS  Google Scholar 

  15. Faivre S, Delbaldo C, Vera K, et al. (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24: 25–35

    Article  PubMed  CAS  Google Scholar 

  16. Motzer RJ, Michaelson MD, Redman BG, et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16–24

    Article  PubMed  CAS  Google Scholar 

  17. Motzer RJ, Rini BI, Bukowski RM, et al. (2006) Sunitinib in Patients with Metastatic Renal Cell Carcinoma. JAMA: The Journal of the American Medical Association; 295: 2516–24

    Article  CAS  Google Scholar 

  18. Motzer RJ, Hutson TE, Tomczak P, et al. (2007) Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. N Engl J Med 356: 115–24

    Article  PubMed  CAS  Google Scholar 

  19. Maki RG, Fletcher JA, Heinrich MC, et al. (2005) Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol (Meeting Abstract); 23: 9011

    Google Scholar 

  20. Heinrich MC, Maki RG, Corless CL, et al. (2006) Sunitinib (SU) response in imatinibresistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol (Meeting Abstracts); 24: 9502

    Google Scholar 

  21. Demetri GD, van Oosterom AT, Garrett CR, et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329–38

    Article  PubMed  CAS  Google Scholar 

  22. Rini BI, Tamaskar I, Shaheen P, et al. (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99: 81–3

    Article  PubMed  CAS  Google Scholar 

  23. De Mulder PH, Roigas J, Gillessen S, et al. (2006) A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts) 24: 4529

    Google Scholar 

  24. Miller KD, Burstein HJ, Elias AD, et al. (2005) Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts) 23: 563

    Google Scholar 

  25. Socinski MA, Novello S, Sanchez JM, et al. (2006) Efficacy and safety of sunitinib in a multicenter phase II trial of previously treated, advanced non-small cell lung cancer (NSCLC). Ann Oncol 17, ix218

    Google Scholar 

  26. Kulke MH, Lenz HJ, Meropol NJ (2005) A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). J Clin Oncol (Meeting Abstracts) 23: 4008

    Google Scholar 

  27. Wood JM, Bold G, Buchdunger E, et al. (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60: 2178–89

    PubMed  CAS  Google Scholar 

  28. Thomas AL, Morgan B, Horsfield MA, et al. (2005) Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23: 4162–71

    Article  PubMed  CAS  Google Scholar 

  29. Hecht JR, Trarbach T, Jaeger E, et al. (2005) A randomized, double-blind, placebocontrolled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol (Meeting Abstracts) 23: LBA3

    Google Scholar 

  30. Koehne C, Bajetta E, Lin E, et al. (2006) Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). J Clin Oncol (Meeting Abstracts); 24: 3508

    Google Scholar 

  31. Major P, Trarbach T, Lenz H, et al. (2006) A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts. J Clin Oncol (Meeting Abstracts) 24: 3529

    Google Scholar 

  32. Conrad C, Friedman H, Reardon D, et al. (2004) A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol (Meeting Abstracts) 22: 1512

    Google Scholar 

  33. Reardon D, Friedman H, Yung WKA, et al. (2004) A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol (Meeting Abstracts) 221: 513

    Google Scholar 

  34. George DJ, Michaelson MD, Oh DK, Reitsma D (2003) A phase I study of single-agent PTK 787/ZK 222584 (PTK/ZK) in metastatic renal carcinoma. J Clin Oncol (Meeting Abstracts); 22: 1548

    Google Scholar 

  35. Besse B, Gauler T, Fischer B, et al. (2006) Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 orally administrated once daily or twice daily at 1250 mg as second-line monotherapy in patients (pts) with stage IIIB or stage IV non-small-cell lung cancer (NSCLC). Ann Oncol 17: ix218–ix219

    Article  Google Scholar 

  36. Morgan B, Thomas AL, Drevs J, et al. (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response to PTK/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients withadvanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21: 3955–64

    Article  PubMed  CAS  Google Scholar 

  37. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, et al. (2005) Soluble markers for the assessment of the biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phases I trials. Ann Oncol 16: 558–65

    Article  PubMed  CAS  Google Scholar 

  38. Miller KD, Trigo JM, Wheeler C, et al. (2005) A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 11: 3369–76

    Article  PubMed  CAS  Google Scholar 

  39. Heymach JV, Johnson BE, Prager D, et al. (2006) A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. J Clin Oncol (Meeting Abstracts); 24: 7016

    Google Scholar 

  40. Natale RB, Bodkin D, Govindan R, et al. (2006) ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial. J Clin Oncol (Meeting Abstracts) 24: 7000

    Google Scholar 

  41. Nakagawa K, Kiura K, Shinkai T, et al. (2006) A randomized double-blind phase IIa dose-finding study of ZD6474 in Japanese patients with NSCLC. J Clin Oncol (Meeting Abstracts) 24: 7067

    Google Scholar 

  42. Rugo HS, Herbst RS, Liu G, et al. (2005) Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results. J Clin Oncol 23: 5474–83

    Article  PubMed  CAS  Google Scholar 

  43. Rini B, Rixe O, Bukowski R, et al. (2005) AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol (Meeting Abstracts) 23: 4509

    Google Scholar 

  44. Kim S, Rosen LS, Cohen EE et al. (2006) A Phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer. J Clin Oncol (Meeting Abstracts) 24: 5529

    Google Scholar 

  45. Tolcher A, O’Leary JJ, deBono JS, et al. (2003) A phase I and biologic correlative study of an oral vascular endothelial growth factor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 21

    Google Scholar 

  46. Cohen RB, Langer CJ, Simon GR, et al. (2007) A phase I/randomized phase II, noncomparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cancer Chemother Pharmacol 60: 81–9

    Article  PubMed  CAS  Google Scholar 

  47. Wedge SR, Kendrew J, Hennequin LF, et al. (2005) AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer. Cancer Res 65: 4389–400

    Article  PubMed  CAS  Google Scholar 

  48. Drevs J, Medinger M, Mross K, et al. (2005) Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. J Clin Oncol (Meeting Abstracts) 23: 3002

    Google Scholar 

  49. Lorusso PM, Heath E, Valdivieso M, Pilat M (2006) Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors. Journal of Clinical OncologyASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S: 3034

    Google Scholar 

  50. Laurie SA, Arnold A, Gauthier I, et al. (2006) Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C)+paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). J Clin Oncol (Meeting Abstracts) 24: 3054

    Google Scholar 

  51. van Cruijsen H, Voest EE, van Herpen CML, et al. (2005) Phase I clinical evaluation of AZD2171 in combination with gefitinib, in patients with advanced tumors. J Clin Oncol (Meeting Abstracts) 23: 3030

    Google Scholar 

  52. Azad NS, Posadas EM, Kwitkowski VE, et al. (2006) Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. J Clin Oncol (Meeting Abstracts) 24: 3004

    Google Scholar 

  53. DePrimo SE, Friece C, Huang X, et al. (2006) Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer. J Clin Oncol (Meeting Abstracts) 24: 578

    Google Scholar 

  54. Norden-Zfoni A, Manola J, Desai J, et al. (2005) Levels of circulating endothelial cells (CECs) and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) with metastatic imatinib-resistant GIST. J Clin Oncol (Meeting Abstracts) 23: 9036

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département de médecine, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94800, Villejuif

    Y. Loriot & B. Besse

Authors
  1. Y. Loriot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Besse
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag France

About this chapter

Cite this chapter

Loriot, Y., Besse, B. (2008). Molécules inhibitrices des récepteurs du VEGF. In: Les thérapies ciblées. Oncologie pratique. Springer, Paris. https://doi.org/10.1007/978-2-287-36008-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-36008-4_5

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-36007-7

  • Online ISBN: 978-2-287-36008-4

Publish with us

Policies and ethics

Search

Navigation